Lercanidipine HCl 20mg Tablets
What this means
The MHRA has issued a medicines recall or defect notification. Class 1: risk to life, immediate recall. Class 2: may cause mistreatment or harm, recall within 48 hours. Class 3: unlikely to cause harm, recall within 5 days. Class 4 (defect notification): no recall, caution in use. The medicine remains licensed; only the listed batches are affected. Do not stop treatment without speaking to your doctor or pharmacist.
Class 2 recall
| Product | Licence | Active ingredient | GTIN |
|---|---|---|---|
| Lercanidipine HCl 20mg Tablets | PL: 04595/0011 | lercanidipine hydrochloride | 8057742821983 |
Batches (expiry): MD4L07 (01/2028)
Background: Recordati Pharmaceuticals Limited has informed the MHRA of an error in the strength of the product printed on some of the faces (sides) of the product carton. The error is limited to the batch of Lercanidipine HCl 20mg Tablets listed in the table above. The packs of 20mg tablets are incorrectly labelled as 10mg on some sides of the product carton. The correct strength (20mg) is printed on the top of the carton and on the blister strips. Recordati Pharmaceuticals Limited is initiating a recall of the specified batch as a precautionary measure. Advice for Healthcare Professionals: Stop supplying the above batch immediately. Quarantine all stock and return it to your supplier using your supplier’s approved process. This medicine is being recalled as a precautionary measure. Pharmacists who have been supplied this batch and suspect they have dispensed the tablets to patients should conta